Evidence map›Paper›PMID 31303175›Full record

ArticleInfectious diseases of poverty2019

The positive influence the Onchocerciasis Elimination Program for the Americas has had on Africa programs.

Frank O Richards, B E B Nwoke, Isam Zarroug, Edridah Tukahebwa, Nebiyu Negussu, T B Higazi, David Oguttu, Zerihun Tadesse, Emmanuel Miri, Nabil Aziz and 2 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases of poverty, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Mass drug administration for endemic scabies: a systematic review.Tropical diseases, travel medicine and vaccines · 2021
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Frank O RichardsThe Carter Center, One Copenhill Avenue, 453 Freedom Parkway, Atlanta, GA, 30307, USA. frank.richards@cartercenter.org.
B E B NwokeImo State University Owerri, PMB 2000, Owerri, Nigeria.
Isam ZarrougSudan Ministry of Health, P.O. Box 303, Khartoum, Sudan.
Edridah TukahebwaUganda Ministry of Health, 15 Bombo Rd., P. O. Box 1661, Kampala, Uganda.
Nebiyu NegussuEthiopia Federal Ministry of Health, P. O. Box 1234, Addis Ababa, Ethiopia.
T B HigaziOhio University, 1425 Newark Rd, Zanesville, OH, 43701, USA.
David OguttuUganda Ministry of Health, 15 Bombo Rd., P. O. Box 1661, Kampala, Uganda.
Zerihun TadesseThe Carter Center-Ethiopia, P. O. Box 13373, Bole K. K. Kebele 05, Addis Ababa, Ethiopia.
Emmanuel MiriThe Carter Center-Nigeria, No. 1 Jeka Kadima St, Jos, Plateau State, Nigeria.
Nabil AzizThe Carter Center-Sudan, P. O. Box 48, Khartoum, Sudan.
Peace HabomugishaThe Carter Center-Uganda, P.O. Box 12027, Kampala, Uganda.
Moses KatabarwaThe Carter Center, One Copenhill Avenue, 453 Freedom Parkway, Atlanta, GA, 30307, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A recent article "Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes" in Infectious Diseases of Poverty claimed that undue influence on African programs by concepts developed by the Onchocerciasis Elimination Program of the Americas (OEPA) is detrimental to stopping mass drug administration (MDA) in Africa. This claim is made despite a record year for MDA stoppage in four African countries of > 3.5 million treatments in 2018, far exceeding any past OEPA or African Program for Onchocerciasis Control (APOC) stop MDA success.

Indexed as

AfricaAmericasAnimalsDisease EradicationFilaricidesHumansIvermectinMass Drug AdministrationOnchocerca volvulusOnchocerciasis, OcularFilaricidesIvermectinEliminationIvermectin mass drug administrationOnchocerciasisOnchocerciasis control Programme for West AfricaTest for antibody to Onchocerca volvulus 16 kDa antigen

Identifiers

PMID31303175
PMCPMC6628490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.